|
|
|
|
 |
Volume 12, Issue 1 (4-2023) |
 |
|
|
|
|
CRISPR and biosafety considerations
|
Atefeh Amini Neisiani    , Abbas Saidi , Masoud Tohidfar * |
| Shahid Beheshti University , gtohidfar@yahoo.com |
|
|
Abstract: (1938 Views) |
With the discovery and development of CRISPR, genome engineering, and gene therapy have been revolutionized. Genome editing research is expanding globally, and this technology is increasingly used in agriculture and medicine. The global CRISPR technology market was estimated to be around $3.4 billion in 2022 and is expected to grow at a rapid rate of 22.3% to reach $9.2 billion in 2027. One of the advantages of this technology is that it can perform targeted gene editing in a short time, unlike traditional breeding methods. Despite the many advantages that CRISPR has for treating diseases and improving human health, there are also biosafety concerns associated with the development and use of this technology. Among these concerns are the presence of off-targets, concerns about the appropriate vectors used in this technology, the different transfer methods, and gene drive. The rules for using products from this technology in some countries are the same as the existing regulatory rules for transgenic products. Some other countries do not consider these products as transgenic products and these products are exempt from the regulations, similarly to products derived from traditional breeding. This review also mentions the existing laws for the use of CRISPR products in some countries of the world. |
|
| Keywords: Crisper Global Market, Management Strategies, Biosafety rules, Biosafety regulations, Genome editing |
|
|
Full-Text [PDF 723 kb]
(504 Downloads)
|
Type of Study: Review |
Subject:
Biosafety
Received: 2023/04/10 | Accepted: 2023/05/26 | Published: 2023/06/16
|
|
|
|
|
|
|
| Add your comments about this article |
|
|
|
|
|
|
|
|
|
|
|
